OptiNose Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.99
Dividend & YieldN/A$ (N/A)
Beta -0.09
Market capitalization 192.22M
Operating cash flow -66.69M
ESG Scores unknown

Company description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio2.51
Working Capital-0.81
Return On Equity3.78
Debt To Equity-5.81
Fixed Asset Ratio1.71
Fixed Interest Cover-4.16

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 3.17M -3.86M 2.2M 2.56M
Total Cashflows From Investing Activities -1.69M -557k -546k -62k
Net Borrowings -2.58M -2.58M 50M
Total Cash From Financing Activities 59.58M 37.53M 83.81M 43.32M
Change To Operating Activities 9.19M 11.89M 13.56M 5.19M
Issuance Of Stock 66.2M 43.48M 34.69M 43.55M
Net Income -106.66M -110.05M -99.78M -82.3M
Change In Cash -33.86M -53.85M -2.99M -33.66M
Effect Of Exchange Rate 64k -3k -44k 13k
Total Cash From Operating Activities -91.82M -90.81M -86.21M -76.94M
Depreciation 539k 1.11M 1.46M 646k
Change To Account Receivables -2.31M -11.33M -10.43M -11.82M
Other Cashflows From Financing Activities -6.55M -3.37M -883k -227k
Change To Netincome 8.54M 17.02M 11.03M 9.7M
Capital Expenditures -1.69M -557k -546k -167k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 10.1M 20.78M 23.38M 25.32M
Income Before Tax -106.66M -110.05M -99.78M -82.3M
Net Income -106.66M -110.05M -99.78M -82.3M
Selling General Administrative 95.62M 104.16M 105.44M 106.63M
Gross Profit 5.48M 29.34M 41.6M 65.5M
Ebit -100.24M -95.6M -87.22M -66.45M
Operating Income -100.24M -95.6M -87.22M -66.45M
Interest Expense -9.23M -9.62M -13.01M -15.97M
Income Tax Expense
Total Revenue 7.07M 34.63M 49.12M 74.65M
Cost Of Revenue 1.59M 5.29M 7.52M 9.15M
Total Other Income ExpenseNet -6.42M -14.45M -12.57M -15.85M
Net Income From Continuing Ops -106.66M -110.05M -99.78M -82.3M
Net Income Applicable To Common Shares -106.66M -110.05M -99.78M -82.3M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 98.38M 111.07M 182.03M 187.84M
Total Stockholder Equity 118.61M 61.58M 6.79M -21.77M
Other Current Liabilities 160k
Total Assets 216.99M 172.65M 188.81M 166.07M
Common Stock 41k 46k 53k 82k
Other Current Assets 21k 23k 13k
Retained Earnings -317.93M -427.98M -527.76M -610.06M
Treasury Stock -57k -48k -85k -81k
Cash 200.99M 147.14M 144.16M 110.5M
Total Current Liabilities 25.7M 36.14M 52.17M 59.23M
Other Stockholder Equity -57k -48k -85k -81k
Property, Plant, and Equipment 3.88M 4.44M 8.01M 5.4M
Total Current Assets 212.86M 168.06M 180.65M 160.38M
Net Tangible Assets 118.61M 61.58M 6.79M -21.77M
Net Receivables 2.55M 13.64M 23.39M 35.45M
Accounts Payable 7.12M 3.62M 5.49M 8.01M


Insider Transactions

Here are the insider transactions of stock shares related to OptiNose Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
MILLER PETER KSale at price 3.55 - 3.56 per share.D2022-09-20Chief Executive Officer53.45k
MARINO MICHAEL F IIISale at price 3.55 - 3.56 per share.D2022-09-20Officer2.73k
MAHMOUD RAMY ASale at price 3.55 - 3.56 per share.D2022-09-20President26.61k
CLAVELLI VICTOR M.Sale at price 3.55 - 3.56 per share.D2022-09-20Officer3.19k
JANIS MICHELESale at price 3.55 - 3.56 per share.D2022-09-20Chief Financial Officer1.74k
MILLER PETER KStock Award(Grant) at price 0.00 per share.D2022-09-15Chief Executive Officer10.85k
MARINO MICHAEL F IIIStock Award(Grant) at price 0.00 per share.D2022-09-15Officer3.82k
MAHMOUD RAMY AStock Award(Grant) at price 0.00 per share.D2022-09-15President6.11k
CLAVELLI VICTOR M.Stock Award(Grant) at price 0.00 per share.D2022-09-15Officer2.5k
JANIS MICHELEStock Award(Grant) at price 0.00 per share.D2022-09-15Chief Financial Officer1.33k
MILLER PETER KSale at price 3.49 per share.D2022-06-16Chief Executive Officer51.74k
MARINO MICHAEL F IIISale at price 3.49 per share.D2022-06-16Officer10.79k
MAHMOUD RAMY ASale at price 3.49 per share.D2022-06-16President28.07k
CLAVELLI VICTOR M.Sale at price 3.49 per share.D2022-06-16Officer9.01k
JANIS MICHELESale at price 3.49 per share.D2022-06-16Chief Financial Officer3.85k
MILLER PETER KStock Award(Grant) at price 0.00 per share.D2022-06-15Chief Executive Officer86.8k
MARINO MICHAEL F IIIStock Award(Grant) at price 0.00 per share.D2022-06-15Officer30.53k
MAHMOUD RAMY AStock Award(Grant) at price 0.00 per share.D2022-06-15President48.91k
CLAVELLI VICTOR M.Stock Award(Grant) at price 0.00 per share.D2022-06-15Officer20k
JANIS MICHELEStock Award(Grant) at price 0.00 per share.D2022-06-15Chief Financial Officer10.67k
MILLER PETER KSale at price 2.11 per share.D2022-03-16Chief Executive Officer25.97k
GOLDAN KEITH ASale at price 2.11 per share.D2022-03-16Chief Financial Officer4.62k
MARINO MICHAEL F IIISale at price 2.11 per share.D2022-03-16Officer4.62k
MAHMOUD RAMY ASale at price 2.11 per share.D2022-03-16President8.22k
CLAVELLI VICTOR M.Sale at price 2.11 per share.D2022-03-16Officer5.71k
MILLER PETER KStock Award(Grant) at price 0.00 per share.D2022-01-11Chief Executive Officer215.5k
GOLDAN KEITH AStock Award(Grant) at price 0.00 per share.D2022-01-11Chief Financial Officer56.73k
MARINO MICHAEL F IIIStock Award(Grant) at price 0.00 per share.D2022-01-11Officer56.73k
MAHMOUD RAMY AStock Award(Grant) at price 0.00 per share.D2022-01-11President59.19k
CLAVELLI VICTOR M.Stock Award(Grant) at price 0.00 per share.D2022-01-11Officer56.73k
MILLER PETER KSale at price 1.64 per share.D2021-12-16Chief Executive Officer3.77k
GOLDAN KEITH ASale at price 1.64 per share.D2021-12-16Chief Financial Officer580
MARINO MICHAEL F IIISale at price 1.64 per share.D2021-12-16Officer580
MAHMOUD RAMY ASale at price 1.64 per share.D2021-12-16President916
CLAVELLI VICTOR M.Sale at price 1.64 per share.D2021-12-16Officer1.26k
GOLDAN KEITH ASale at price 2.79 per share.D2021-09-16Chief Financial Officer578
MARINO MICHAEL F IIISale at price 2.79 per share.D2021-09-16Officer578
MAHMOUD RAMY ASale at price 2.79 per share.D2021-09-16President12.5k
MILLER PETER KD2021-09-15Chief Executive Officer79.51k
MAHMOUD RAMY AD2021-09-15President39.75k
GOLDAN KEITH ASale at price 3.73 per share.D2021-06-17Chief Financial Officer576
MARINO MICHAEL F IIISale at price 3.73 per share.D2021-06-17Officer576
MAHMOUD RAMY ASale at price 3.73 per share.D2021-06-17President909
CLAVELLI VICTOR M.Purchase at price 3.06 per share.D2021-05-20Officer34k
SCODARI JOSEPH CPurchase at price 2.99 per share.D2021-05-10Director10k
MILLER PETER KPurchase at price 3.85 - 3.91 per share.D2021-03-18Chief Executive Officer12.53k
MILLER PETER KSale at price 3.92 per share.D2021-03-15Chief Executive Officer9.7k
GOLDAN KEITH ASale at price 3.92 per share.D2021-03-15Chief Financial Officer2.3k
MARINO MICHAEL F IIISale at price 3.92 per share.D2021-03-15Officer2.3k
MAHMOUD RAMY ASale at price 3.92 per share.D2021-03-15President3.64k
CLAVELLI VICTOR M.Sale at price 3.92 per share.D2021-03-15Officer5.05k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to OptiNose Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on OptiNose Inc

Here is the result of two systematic investment strategies applied to OptiNose Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on OptiNose Inc

The following chart shows the equity curve of the two systematic investment strategies applied to OptiNose Inc:

OptiNose Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -44.89% on the backtest period.

Performance at glance

Performance

-44.89 %

Latent gain

-1005.19 $

Invested capital

2239.24 $

Annualized return

-10.95 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on OptiNose Inc

This is the result of two momentum investment strategies applied to OptiNose Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on OptiNose Inc

The following chart shows all the entries opened by the momentum investment system on OptiNose Inc:

OptiNose Inc momentum entries
  • The first momentum investment strategy would give -47.24% of return on OptiNose Inc. That represents -2011.06$ of latent gain with 4256.86$ of employed capital.
  • The second momentum investment strategy would give -44.01% of return on OptiNose Inc. That represents -987.85$ of latent gain with 2244.7$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-47.24 %

Latent gain

-2011.06 $

Invested capital

4256.86 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-44.01 %

Latent gain

-987.85 $

Invested capital

2244.7 $

Annualized return

-12.16 %

Momentum equity curve on OptiNose Inc

The following chart shows the equity curve of the two momentum strategies applied to OptiNose Inc:

OptiNose Inc momentum equity

Note: the dividends potentially given by OptiNose Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on OptiNose Inc

The following chart shows the employed capital evolution of the two momentum strategies on OptiNose Inc since the beginning:

OptiNose Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on OptiNose Inc

Buy the dip entry openings on OptiNose Inc

OptiNose Inc

The performance achieved by the robo-advisor on OptiNose Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows OptiNose Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of OptiNose Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to OptiNose Inc

The following chart shows the result of the investment strategy applied to OptiNose Inc:

OptiNose Inc

Note: the dividends potentially given by OptiNose Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on OptiNose Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on OptiNose Inc:

OptiNose Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on OptiNose Inc

In this section, I will compare the three previous investment strategies applied to OptiNose Inc.

Equity curve comparison on OptiNose Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

OptiNose Inc investment strategy comparison

Employed capital comparison on OptiNose Inc

OptiNose Inc investment comparison

Performance comparison on OptiNose Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -44.89% -1005.19$ 2239.24$ -10.95%
Momentum 1 quarter -47.24% -2011.06$ 4256.86$ -12.24%
Momentum 2 quarters -44.01% -987.85$ 2244.7$ -12.16%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-10.95 %

Momentum 1Q

-12.16 %

Momentum 2Q

-12.16 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with OptiNose Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months


Note: The algorithm computes the probability of correlation between OptiNose Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of OptiNose Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name OptiNose Inc
Country United States
City Yardley
Address 1020 Stony Hill Road
Phone 267 364 3500
Website www.optinose.com
FullTime employees 189
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
Exchange XNAS
Ticker OPTN
Market www.nasdaq.com

OptiNose Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown